Literature DB >> 27392888

Long-Term Cell Tracking Following Local Injection of Mesenchymal Stromal Cells in the Equine Model of Induced Tendon Disease.

Janina Burk, Dagmar Berner, Walter Brehm, Aline Hillmann, Carolin Horstmeier, Christoph Josten, Felicitas Paebst, Giacomo Rossi, Susanna Schubert, Annette B Ahrberg.   

Abstract

Tendon disease has been treated with multipotent mesenchymal stromal cells (MSCs) in the equine large-animal model with promising success. The aim of this study was to gain more insight into the fate and biodistribution of MSCs after local application into tendon lesions by long-term cell tracking in this large-animal model. Superficial digital flexor tendon lesions were induced in all limbs in six horses and injected with 10106 Molday ION Rhodamine B-labeled MSCs suspended in serum or serum alone. Follow-up was performed using low-field magnetic resonance imaging (MRI), flow cytometry, and histology. Cell tracking based on the hypointense artifacts induced by the superparamagnetic iron oxide (SPIO) labeling agent in MRI as well as based on Rhodamine B fluorescence was feasible. However, Prussian blue staining for assessment of histology was not entirely specific for SPIO. Labeled cells could be traced at their injection site by MRI as well as histology for the whole follow-up period of 24 weeks. Although the numbers of labeled cells within the injected tendon lesions decreased over time, part of the applied cells appeared to remain viable and integrated within the injured tissue. Furthermore, small numbers of labeled cells were identified in peripheral blood within the first 24 h after cell injection and could also be found until week 24 within the contralateral control tendon lesions that had been injected with serum. The present findings unveil details on MSC biodistribution and persistence after their local application, which are of clinical relevance with regard to MSC safety and mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27392888     DOI: 10.3727/096368916X692104

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  15 in total

1.  Persistence of fluorescent nanoparticle-labelled bone marrow mesenchymal stem cells in vitro and after intra-articular injection.

Authors:  Sicilia T Grady; Lorraine Britton; Katrin Hinrichs; Alan J Nixon; Ashlee E Watts
Journal:  J Tissue Eng Regen Med       Date:  2019-01-23       Impact factor: 3.963

2.  Cyclic tensile tests of Shetland pony superficial digital flexor tendons (SDFTs) with an optimized cryo-clamp combined with biplanar high-speed fluoroscopy.

Authors:  Franziska C Wagner; Sven Reese; Kerstin Gerlach; Peter Böttcher; Christoph K W Mülling
Journal:  BMC Vet Res       Date:  2021-06-25       Impact factor: 2.741

3.  Effect of single intralesional treatment of surgically induced equine superficial digital flexor tendon core lesions with adipose-derived mesenchymal stromal cells: a controlled experimental trial.

Authors:  Florian Geburek; Florian Roggel; Hans T M van Schie; Andreas Beineke; Roberto Estrada; Kathrin Weber; Maren Hellige; Karl Rohn; Michael Jagodzinski; Bastian Welke; Christof Hurschler; Sabine Conrad; Thomas Skutella; Chris van de Lest; René van Weeren; Peter M Stadler
Journal:  Stem Cell Res Ther       Date:  2017-06-05       Impact factor: 6.832

4.  Tenogenic Properties of Mesenchymal Progenitor Cells Are Compromised in an Inflammatory Environment.

Authors:  Luisa Brandt; Susanna Schubert; Patrick Scheibe; Walter Brehm; Jan Franzen; Claudia Gross; Janina Burk
Journal:  Int J Mol Sci       Date:  2018-08-28       Impact factor: 5.923

5.  Growth and function of equine endothelial colony forming cells labeled with semiconductor quantum dots.

Authors:  Randolph L Winter; Wen J Seeto; Yuan Tian; Fred J Caldwell; Elizabeth A Lipke; Anne A Wooldridge
Journal:  BMC Vet Res       Date:  2018-08-23       Impact factor: 2.741

6.  Effects of mesenchymal stromal cells versus serum on tendon healing in a controlled experimental trial in an equine model.

Authors:  A B Ahrberg; C Horstmeier; D Berner; W Brehm; C Gittel; A Hillmann; C Josten; G Rossi; S Schubert; K Winter; J Burk
Journal:  BMC Musculoskelet Disord       Date:  2018-07-18       Impact factor: 2.362

Review 7.  Strategies of tenogenic differentiation of equine stem cells for tendon repair: current status and challenges.

Authors:  Asiyeh Shojaee; Abbas Parham
Journal:  Stem Cell Res Ther       Date:  2019-06-18       Impact factor: 6.832

8.  A novel direct co-culture assay analyzed by multicolor flow cytometry reveals context- and cell type-specific immunomodulatory effects of equine mesenchymal stromal cells.

Authors:  Aline Hillmann; Felicitas Paebst; Walter Brehm; Daniel Piehler; Susanna Schubert; Attila Tárnok; Janina Burk
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

9.  Single and repeated intra-articular injections in the tarsocrural joint with allogeneic and autologous equine bone marrow-derived mesenchymal stem cells are safe, but did not reduce acute inflammation in an experimental interleukin-1β model of synovitis.

Authors:  Aimée C Colbath; Steven W Dow; Leone S Hopkins; Jennifer N Phillips; C Wayne McIlwraith; Laurie R Goodrich
Journal:  Equine Vet J       Date:  2020-02-14       Impact factor: 2.888

10.  Growth Factor-Mediated Tenogenic Induction of Multipotent Mesenchymal Stromal Cells Is Altered by the Microenvironment of Tendon Matrix.

Authors:  Susanne Pauline Roth; Susanna Schubert; Patrick Scheibe; Claudia Groß; Walter Brehm; Janina Burk
Journal:  Cell Transplant       Date:  2018-09-25       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.